Wegovy for sleep apnea: why the OSA coverage path runs through Zepbound, not Wegovy

Wegovy is not approved for sleep apnea. Zepbound is. The obstructive sleep apnea indication belongs to tirzepatide (Zepbound), not semaglutide (Wegovy), on the strength of the SURMOUNT-OSA trial. If you have OSA and want a GLP-1 covered under that diagnosis, ask your prescriber about Zepbound. Getting Wegovy with sleep apnea means going through cash-pay, off-label, or a different qualifying condition.

Some links here earn us a commission. Prices checked Monday, August 17, 2026.

What SURMOUNT-OSA tested

SURMOUNT-OSA was a phase 3 trial of tirzepatide, not semaglutide. It randomized 469 adults with moderate-to-severe OSA and obesity to tirzepatide 15 mg weekly or placebo for 52 weeks. Published in NEJM in June 2024, it showed a mean drop of 25 to 30 apnea events per hour on tirzepatide against about 5 on placebo, disease resolution (AHI under 5) in roughly 43 percent, and 18 to 20 percent body weight loss. On that evidence the FDA approved Zepbound for moderate-to-severe OSA in adults with obesity on December 20, 2024. Wegovy ran no OSA trial and carries no OSA approval.

Why the label decides your coverage

Insurers authorize a drug under its FDA-approved indications, and prior authorization criteria follow the label. A Zepbound PA under OSA cites SURMOUNT-OSA, your AHI from the sleep study, and the approved indication. The same papers submitted for Wegovy match nothing on its label. So a plan that excludes obesity drugs but covers sleep-disorder treatment authorizes Zepbound under OSA and denies Wegovy. On Medicare Part D, Wegovy gets in through the cardiovascular indication (SELECT) and Zepbound through OSA. A plan that requires a failed CPAP trial first accepts that record for Zepbound.

Three ways to get Wegovy with sleep apnea

A different qualifying indication. If you also have established cardiovascular disease (prior heart attack, stroke, or symptomatic peripheral artery disease), Wegovy is approved under the SELECT cardiovascular indication. Roughly 40 percent of moderate-to-severe OSA patients also meet those criteria. The June 2026 Wegovy label opened another door: noncirrhotic MASH with stage F2 to F3 fibrosis, which carries no BMI threshold.

Standard obesity PA. With BMI 30 or higher, or BMI 27 plus a comorbidity, your plan's normal obesity process applies. OSA counts as the comorbidity that satisfies the BMI 27 threshold.

Cash-pay. NovoCare sells Wegovy self-pay at about $349 a month. Compounded semaglutide survives only through a narrow medical-necessity carve-out at some 503A pharmacies, since the FDA closed the shortage in February 2025.

What the PA review does

An OSA-flagged Wegovy request comes back one of three ways. It gets approved under BMI plus comorbidity, the plan treating it as a standard obesity case (3 to 14 business days). It gets denied with a redirect to Zepbound, the most common outcome in 2026. Or it gets denied flat on indication mismatch, leaving you to switch products or appeal. The clean fix is usually to switch the prescription.

The cash-pay math favors Zepbound

Paying cash, NovoCare Wegovy runs about $349 a month and LillyDirect Zepbound vials run $299 to $449 by dose. Zepbound vials are often cheaper, and they carry the matching FDA indication if you later move to insurance billing.

If OSA is your only qualifying condition, the switch to Zepbound is the clean path. See how a primary-care program handles the prescription and PA on the Knownwell review page.

Sources

• Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. NEJM 2024;391:1193-1205. nejm.org
• FDA, December 20 2024. FDA approves first medication for obstructive sleep apnea. fda.gov
• Wegovy prescribing information, Novo Nordisk. accessdata.fda.gov
• Zepbound prescribing information, Eli Lilly. accessdata.fda.gov
• Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM 2023;389:2221-2232. nejm.org